Ferumoxytol Non-Stoichiometric Magnetite
PreclinicalSmall molecule
Ferumoxytol Non-Stoichiometric Magnetite is one of 55 small molecule programs targeting Glioblastoma Multiforme. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Glioblastoma Multiforme
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Avastin
RochePhase 3
Gilenya
NovartisApproved
Istodax
TevaApproved
Lynparza
AstraZenecaApproved
Niacor
AbbVieApproved
Bayer Aspirin
BayerApproved
Keppra
UCBApproved
Cialis
Eli LillyApproved
Talzenna
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- OOHSU Knight Cancer Institute